Komori
Business Alliances7096StemCell InstituteInformation and Communications, Services and Others

StemCell Institute and CellSource Enter into R&D Collaboration on Umbilical Cord-Derived Extracellular Vesicles, Including Exosomes

ステムセル研究所 and セルソース entered into a business alliance for the research and development of extracellular vesicles, including exosomes, secreted by umbilical cord-derived mesenchymal stromal cells. The companies will combine their technologies and expertise to develop a technological foundation for cell culture, quality evaluation and other areas.

Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business Alliances
7096StemCell Institute
Alliance partnerCellSource Co., Ltd.
Details of the alliance
  1. 1

    Conduct technical studies on the culture of umbilical cord-derived mesenchymal stromal cells and extracellular vesicles

  2. 2

    Share necessary information and know-how

  3. 3

    Work to establish an organisational framework for business development

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionRegenerative Medicine-Related Business
LocationShibuya-ku, Tokyo
Impact on Business Performance

The impact of this matter on ステムセル研究所's results is immaterial.

Agreements reached under this partnership
ItemDetails
Name of alliance partnerCellSource Co., Ltd.
Alliance partner's business activitiesRegenerative Medicine-Related Business
Alliance partner's locationShibuya-ku, Tokyo
Type of allianceBusiness Alliances
Details of the allianceConduct technical studies on the culture of umbilical cord-derived mesenchymal stromal cells and extracellular vesicles, Share necessary information and know-how, Work to establish an organisational framework for business development
Impact on Business PerformanceThe impact of this matter on ステムセル研究所's results is immaterial.
Items this document does not state (17)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To combine ステムセル研究所's technologies and expertise in the processing and storage of umbilical cords and umbilical cord blood with セルソース's technologies and expertise in cell processing, quality control and extracellular vesicles, and to build a technological foundation for the use of umbilical cord-derived extracellular vesicles.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
StemCell Institute and CellSource Enter into R&D Collaboration on Umbilical Cord-Derived Extracellular Vesicles, Including Exosomes | StemCell Institute (7096) timely disclosure | Komori